Flashpoint Therapeutics Appoints Barry Labinger as Chief Executive Officer
Flashpoint Therapeutics, a clinical-stage biotechnology company developing a new class of precision-engineered structural nanomedicines, today announced the appointment of Barry Labinger as Chief Executive Officer. With more than three decades of executive experience in the biopharmaceutical industry, Barry brings a proven track record of building and leading innovative life sciences organizations through critical phases of growth, development, and commercialization.
Flashpoint Therapeutics Announces $10M Seed Financing Led by Beta Lab to Pioneer Nanotechnology-Enabled Medicines
Flashpoint Therapeutics, a company developing nanotechnology-enabled therapeutics for cancer and other diseases, announced today a $10M seed financing round led by Beta Lab, a leading deep tech venture capital firm headquartered in Riyadh, Saudi Arabia, with participation from leading private equity investor Russell Carson’s CS Venture Opportunities Fund.
